Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAtla (BCAB) EPS (Weighted Average and Diluted) (2021 - 2025)

BioAtla (BCAB) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.16 as the latest value for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 46.67% year-over-year to -$0.16; the TTM value through Dec 2025 reached -$1.01, up 29.86%, while the annual FY2025 figure was -$1.01, 29.86% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.16 in Q4 2025 for BioAtla, up from -$0.27 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.16 in Q4 2025 and bottomed at -$0.9 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.53, with a median of -$0.58 recorded in 2023.
  • Year-over-year, EPS (Weighted Average and Diluted) skyrocketed 68.57% in 2024 and then dropped 22.73% in 2025.
  • BioAtla's EPS (Weighted Average and Diluted) stood at -$0.63 in 2021, then dropped by 0.0% to -$0.63 in 2022, then grew by 11.11% to -$0.56 in 2023, then skyrocketed by 46.43% to -$0.3 in 2024, then soared by 46.67% to -$0.16 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.16, -$0.27, and -$0.32 for Q4 2025, Q3 2025, and Q2 2025 respectively.